Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group.
Calais da Silva
F
F
Hospital do Desterro, Lisbon, Portugal. urologia@hdesterro.min-saude.pt
Bono
A
A
Whelan
P
P
Brausi
M
M
Queimadelos
M
M
Portillo
J
J
Kirkali
Z
Z
Robertson
C
C
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal